Antibody drug conjugates (ADCs) are a class of targeted drugs composed of a cytotoxic payload linked to an antibody that targets a cancer cell, designed to release the payload specifically at a tumor site to kill the tumor. ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted therapeutic applications. This modality is also being explored using non-toxic payloads for immune modulation, including for indications such as autoimmune disorders.

ADC discovery involves a multidisciplinary approach that combines knowledge from antibody engineering, linker chemistry, and payload selection. Further, the discovery, development, and manufacturing of ADCs present numerous challenges due to the complexity of these molecules and the need to balance efficacy, safety, and manufacturability.

In this White Paper, we explore the key challenges in ADC development and how Syngene, with its end-to-end capabilities, can be a trusted partner in bringing ADC therapies to market at speed.